This site is intended for health professionals only

Cetuximab “boosts cancer survival”


Survival in patients with advanced head and neck cancer is prolonged by adding cetuximab to radiation therapy, according to a report published online first in The Lancet Oncology.

It concludes that as improvement persists for up to five years, it should now be considered as a standard treatment option.

The report notes that most head and neck cancers express the epidermal growth factor receptor (EGFR), and that cetuximab is a monoclonal antibody that specifically targets EGFR.

Trials show that patients treated with cetuximab had a 13% improvement in disease control and 10% in survival at three years without increased side effects.

Overall, findings showed an improvement in absolute survival of about 9% in patients given cetuximab compared with those given radiotherapy alone (36.4% vs 45.6%) at five years.

The report says: “Future studies will be designed to help provide a pathway to individualised patient treatments. The analysis of molecular markers … will help refine our ability to select the patients who will benefit from the various systemic treatments to radiotherapy.”

Copyright © Press Association 2009

The Lancet Oncology

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine